N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

VEDA Study (DHEA vs Estradiol)

Sponsor: University of Arizona • ClinicalTrials.gov ID: NCT07574216

Registry updated: 2026-09-21
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study is being done to compare two vaginal treatments, vaginal estrogen and vaginal DHEA, that are used to treat vaginal and urinary symptoms related to menopause. These symptoms may include vaginal dryness, discomfort, painful intercourse, or urinary problems and can affect quality of life and sexual health. Women who choose to participate will be randomly assigned to use one of the two treatments for a set period of time. Participants will complete questionnaires about their symptoms and sexual health and have simple vaginal testing at the beginning and end of the study. The goal of this research is to better understand how these treatments affect vaginal health and sexual function so healthcare providers can make informed treatment decisions and improve care for postmenopausal women.

Interventions

  • DHEA ovals (Drug)
    DHEA (dehydroepiandrosterone) is an inactive hormone precursor naturally produced by the body. When placed locally in the vagina, it is converted by vaginal cells into small amounts of estrogen and androgens exactly where the tissues need them. This helps restore the vaginal lining, improve moisture, and reduce pain.
  • Estradiol 0.01% Vag Cream (Drug)
    Estradiol 0.01% vaginal cream is a local (vaginal) estrogen therapy used to treat symptoms of genitourinary syndrome of menopause (GSM)-the thinning, dryness, and inflammation of vaginal and urinary tissues caused by postmenopausal estrogen decline.

Eligibility criteria

Inclusion Criteria: * Peri- or post-menopausal status * Presence of any genitourinary or vaginal symptom (e.g., dryness, itching, discomfort, dyspareunia) * Willingness and ability to use vaginal therapy * Ability to provide informed consent * English speaker * Ages 40-90 Exclusion Criteria: * Use of systemic hormone therapy within the last 6 months * Gynecologic malignancy * Known allergy to study medications * Active vaginal infection at enrollment * Prior pelvic radiation

Conditions

Post-menopause Pre-menopause Sexual Function Menopause Vaginal Dryness Painful Intercourse

Locations

  • Banner University Medical Center Phoenix — Phoenix, Arizona, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record